Genetically Engineered War Dogs Enter U.S. Defense Pipeline in $200M Venture

The U.S. military has long depended on imported canines for critical tasks, but a new venture emerging from stealth on Thursday seeks to bring that production back to American soil through genetic engineering. Warhound, a startup backed by $200 million in fresh capital, plans to develop purpose-built dogs for defense, law enforcement, and emergency response sectors.

The funding round, which values the company at $1.2 billion, includes participation from prominent investors such as Sequoia, 8VC, and Corner Ventures. Notably, In-Q-Tel, a venture firm supported by the CIA and other U.S. intelligence agencies, also joined the round. This financial backing signals a significant bet on the viability of biotech solutions for military logistics.

The core problem Warhound addresses is a shrinking domestic supply of working dogs. According to the company’s launch materials, more than 80% of the U.S. military’s current canine workforce is sourced from Europe. Furthermore, fewer than half of these imported animals are deemed fit for service upon arrival. This reliance on foreign nations creates a vulnerability in the supply chain for animals that perform dangerous duties, including bomb detection and specialized searches.

The project is a collaboration between Ben Lamm of Colossal Biosciences and Palmer Luckey of Anduril. Lamm explained that he met Luckey at a conference about a year ago, where Luckey expressed frustration with the state of military working dogs. Lamm subsequently researched breeding practices and identified that many dogs fail training due to inherited issues such as poor eyesight, cancer predispositions, hip dysplasia, or muscle atrophy.

To combat these biological limitations, Warhound is utilizing technology from Colossal, a company known for its de-extinction efforts involving animals like the mammoth and dodo. The team has established a biobank using cell lines from top-performing breeds, specifically the Belgian Malinois and German Shepherd. The plan is to edit these genes to enhance traits like speed, agility, and olfactory sensitivity while removing genes associated with health problems, effectively creating a new type of military dog.

Anduril will play a crucial role by supplying the hardware and software necessary for these animals to operate effectively. This includes protection vests, goggles, and other gear designed to improve situational awareness for both the dog and its human handler. Lamm described the concept as adding capabilities "on top of the dog, not in the dog," such as bulletproof vests with data sensors that relay information to handlers. This approach aims to make the animals safer and more effective in the line of duty.

While Luckey is a partner in the venture, he holds no equity, whereas Colossal owns a stake and licenses its technology to Warhound. The cloning process will be handled by Viagen, another Colossal-owned company, which Lamm said has a high success rate. The first batch of dogs is expected to be cloned and incubated soon, with births anticipated early next year and service beginning within two years. The company has not yet determined pricing but expects to sell to the Department of Defense, police forces, and first responders.

To address concerns about animal welfare, Warhound is working under the guidance of the American Humane Society to certify its training programs. The society stated that it looks forward to ensuring the animals are treated humanely and that retired dogs can enter its reunification programs. Lamm noted that each dog will be trained like any standard military working dog and managed by its purchaser, ensuring civilian safety protocols are met.